News and Analysis | Published:

Small molecules against RNA targets attract big backers

Nature Reviews Drug Discovery volume 16, pages 813815 (2017) | Download Citation

Novartis, Merck, Pfizer and biotech entrepreneurs have started working on small-molecule drugs that act on an assortment of RNA targets, hoping to unlock once undruggable targets and new biology.

  • Subscribe to Nature Reviews Drug Discovery for full access:

    $265

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2017.239

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

Authors

  1. Search for Asher Mullard in: